Q-omics provides the consensus-scored JRKL-AS1 profile across patient tissues and cancer cell-line models. JRKL-AS1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, JRKL-AS1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, JRKL-AS1 RNA expression shows 6,537 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRC, and STAD as cancer lineages where JRKL-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JRKL-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JRKL-AS1 survival associations across molecular data types. JRKL-AS1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JRKL-AS1 RNA expression–survival associations across cancer types. High JRKL-AS1 expression shows unfavorable associations in LUAD, BRCA, HNSC, KIRP and CESC, but favorable associations in BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for JRKL-AS1 RNA expression.
This table summarizes JRKL-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for JRKL-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JRKL-AS1 shows lower tumor expression in KIRC and higher tumor expression in LUAD, UCEC, LUSC, BRCA and HNSC. The KIRC box plot shows higher JRKL-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.101, t-test p = .012).
This table shows molecular features associated with JRKL-AS1 in patient tissues and cancer cell lines. In patient samples, JRKL-AS1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
